KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Amortizatization of Intangibles for 17 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 35.92% year-over-year to $1.1 million, compared with a TTM value of $4.8 million through Dec 2025, down 42.47%, and an annual FY2025 reading of $4.8 million, down 42.47% over the prior year.
  • Amortizatization of Intangibles was $1.1 million for Q4 2025 at Biomarin Pharmaceutical, up from $978000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.6 million in Q2 2023 and bottomed at -$1.9 million in Q4 2021.
  • Average Amortizatization of Intangibles over 5 years is $708800.0, with a median of $1.2 million recorded in 2025.
  • The sharpest move saw Amortizatization of Intangibles plummeted 5577.27% in 2021, then surged 435.02% in 2023.
  • Year by year, Amortizatization of Intangibles stood at -$1.9 million in 2021, then surged by 137.21% to $698000.0 in 2022, then soared by 250.57% to $2.4 million in 2023, then dropped by 29.46% to $1.7 million in 2024, then crashed by 35.92% to $1.1 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for BMRN at $1.1 million in Q4 2025, $978000.0 in Q3 2025, and $1.4 million in Q2 2025.